ReviewStem cell reviews2006
Human artificial chromosome vectors meet stem cells: new prospects for gene delivery.
Review in Stem cell reviews, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Understanding the molecular basis of autism in a dish using hiPSCs-derived neurons from ASD patients.Molecular brain · 2015Review
- Mouse embryonic stem cells with a multi-integrase mouse artificial chromosome for transchromosomic mouse generation.Transgenic research · 2015Article
- De novo formed satellite DNA-based mammalian artificial chromosomes and their possible applications.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2015Review
- Advances in understanding the cell types and approaches used for generating induced pluripotent stem cells.Journal of hematology & oncology · 2014Review
- Article
- Protecting a transgene expression from the HAC-based vector by different chromatin insulators.Cellular and molecular life sciences : CMLS · 2013Article
- Re-engineering an alphoid(tetO)-HAC-based vector to enable high-throughput analyses of gene function.Nucleic acids research · 2013Article
- A new generation of human artificial chromosomes for functional genomics and gene therapy.Cellular and molecular life sciences : CMLS · 2013Review
- Organization of synthetic alphoid DNA array in human artificial chromosome (HAC) with a conditional centromere.ACS synthetic biology · 2012Article
- Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy.ISRN oncology · 2012Article
- Progress and prospects: human artificial chromosomes.Gene therapy · 2009Review
- Interspecific transfer of mammalian artificial chromosomes between farm animals.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2009Article
- Recent advances in gene therapy for severe congenital immunodeficiency diseases.Current opinion in hematology · 2008Review
- Scalable human ES culture for therapeutic use: propagation, differentiation, genetic modification and regulatory issues.Gene therapy · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent emergence of stem cell-based tissue engineering has now opened up new venues for gene therapy. The task now is to develop safe and effective vectors that can deliver therapeutic genes into specific stem cell lines and maintain long-term regulated expression of these genes. Human artificial chromosomes (HACs) possess several characteristics that require gene therapy vectors, including a stable episomal maintenance, and the capacity for large gene inserts. HACs can also carry genomic loci with regulatory elements, thus allowing for the expression of transgenes in a genetic environment similar to the chromosome. Currently, HACs are constructed by a two prone approaches. Using a top-down strategy, HACs can be generated from fragmenting endogenous chromosomes. By a bottom-up strategy, HACs can be created de novo from cloned chromosomal components using chromosome engineering. This review describes the current advances in developing HACs, with the main focus on their applications and potential value in gene delivery, such as HAC-mediated gene expression in embryonic, adult stem cells, and transgenic animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.